{"record_type":"pith_number_record","schema_url":"https://pith.science/schemas/pith-number/v1.json","pith_number":"pith:2024:UZIQVCZURPE6EQZVK4XNANZBJS","short_pith_number":"pith:UZIQVCZU","schema_version":"1.0","canonical_sha256":"a6510a8b348bc9e24335572ed037214cbf0908721ef1418a853ebd7216b3bcac","source":{"kind":"arxiv","id":"2402.08334","version":1},"attestation_state":"computed","paper":{"title":"An Executable Specification of Oncology Dose-Escalation Protocols with Prolog","license":"http://creativecommons.org/licenses/by/4.0/","headline":"","cross_cats":[],"primary_cat":"cs.PL","authors_text":"David C. Norris, Markus Triska","submitted_at":"2024-02-13T09:57:46Z","abstract_excerpt":"We present, as a pure Prolog program, the first executable specification of the 3 + 3 dose-escalation protocol commonly used in early-phase oncology drug development. In this program, the imperative operations of the protocol emerge as consequences of clinically meaningful anticipatory-regret scenarios that are declared as CLP(Z) constraints. This 'regret-constrained' (RC) specification yields a robust formulation which can be used to prove clinically meaningful safety and liveness properties of the protocol before incorporating it into a trial, and then as an on-line decision support system w"},"verification_status":{"content_addressed":true,"pith_receipt":true,"author_attested":false,"weak_author_claims":0,"strong_author_claims":0,"externally_anchored":false,"storage_verified":false,"citation_signatures":0,"replication_records":0,"graph_snapshot":true,"references_resolved":false,"formal_links_present":false},"canonical_record":{"source":{"id":"2402.08334","kind":"arxiv","version":1},"metadata":{"license":"http://creativecommons.org/licenses/by/4.0/","primary_cat":"cs.PL","submitted_at":"2024-02-13T09:57:46Z","cross_cats_sorted":[],"title_canon_sha256":"75be037d6934163fa6a0b6092d6101c85897591dcf782672bcf33982bb1242e0","abstract_canon_sha256":"5ac6ad6ace55150ba77db077004e3285652bd1d5c572e6d448d9401691bc8367"},"schema_version":"1.0"},"receipt":{"kind":"pith_receipt","key_id":"pith-v1-2026-05","algorithm":"ed25519","signed_at":"2026-07-05T07:44:31.112783Z","signature_b64":"32tTbNY/1+7Jh7PdVbP7rtuPdPb++TxSvKULVD9S2vZvVHzLpbh/QgcuguBVyyPcCZG/HzGD6473fxc2GU4gBw==","signed_message":"canonical_sha256_bytes","builder_version":"pith-number-builder-2026-05-17-v1","receipt_version":"0.3","canonical_sha256":"a6510a8b348bc9e24335572ed037214cbf0908721ef1418a853ebd7216b3bcac","last_reissued_at":"2026-07-05T07:44:31.112343Z","signature_status":"signed_v1","first_computed_at":"2026-07-05T07:44:31.112343Z","public_key_fingerprint":"8d4b5ee74e4693bcd1df2446408b0d54"},"graph_snapshot":{"paper":{"title":"An Executable Specification of Oncology Dose-Escalation Protocols with Prolog","license":"http://creativecommons.org/licenses/by/4.0/","headline":"","cross_cats":[],"primary_cat":"cs.PL","authors_text":"David C. Norris, Markus Triska","submitted_at":"2024-02-13T09:57:46Z","abstract_excerpt":"We present, as a pure Prolog program, the first executable specification of the 3 + 3 dose-escalation protocol commonly used in early-phase oncology drug development. In this program, the imperative operations of the protocol emerge as consequences of clinically meaningful anticipatory-regret scenarios that are declared as CLP(Z) constraints. This 'regret-constrained' (RC) specification yields a robust formulation which can be used to prove clinically meaningful safety and liveness properties of the protocol before incorporating it into a trial, and then as an on-line decision support system w"},"claims":{"count":0,"items":[],"snapshot_sha256":"258153158e38e3291e3d48162225fcdb2d5a3ed65a07baac614ab91432fd4f57"},"source":{"id":"2402.08334","kind":"arxiv","version":1},"verdict":{"id":null,"model_set":{},"created_at":null,"strongest_claim":"","one_line_summary":"","pipeline_version":null,"weakest_assumption":"","pith_extraction_headline":""},"integrity":{"clean":true,"summary":{"advisory":0,"critical":0,"by_detector":{},"informational":0},"endpoint":"/pith/2402.08334/integrity.json","findings":[],"available":true,"detectors_run":[],"snapshot_sha256":"c28c3603d3b5d939e8dc4c7e95fa8dfce3d595e45f758748cecf8e644a296938"},"references":{"count":0,"sample":[],"resolved_work":0,"snapshot_sha256":"258153158e38e3291e3d48162225fcdb2d5a3ed65a07baac614ab91432fd4f57","internal_anchors":0},"formal_canon":{"evidence_count":0,"snapshot_sha256":"258153158e38e3291e3d48162225fcdb2d5a3ed65a07baac614ab91432fd4f57"},"author_claims":{"count":0,"strong_count":0,"snapshot_sha256":"258153158e38e3291e3d48162225fcdb2d5a3ed65a07baac614ab91432fd4f57"},"builder_version":"pith-number-builder-2026-05-17-v1"},"aliases":[{"alias_kind":"arxiv","alias_value":"2402.08334","created_at":"2026-07-05T07:44:31.112408+00:00"},{"alias_kind":"arxiv_version","alias_value":"2402.08334v1","created_at":"2026-07-05T07:44:31.112408+00:00"},{"alias_kind":"doi","alias_value":"10.48550/arxiv.2402.08334","created_at":"2026-07-05T07:44:31.112408+00:00"},{"alias_kind":"pith_short_12","alias_value":"UZIQVCZURPE6","created_at":"2026-07-05T07:44:31.112408+00:00"},{"alias_kind":"pith_short_16","alias_value":"UZIQVCZURPE6EQZV","created_at":"2026-07-05T07:44:31.112408+00:00"},{"alias_kind":"pith_short_8","alias_value":"UZIQVCZU","created_at":"2026-07-05T07:44:31.112408+00:00"}],"events":[],"event_summary":{},"paper_claims":[],"inbound_citations":{"count":1,"internal_anchor_count":1,"sample":[{"citing_arxiv_id":"2507.01370","citing_title":"Dose-Escalation Trial Protocols that Extend Naturally to Admit Titration","ref_index":13,"is_internal_anchor":true}]},"formal_canon":{"evidence_count":0,"sample":[],"anchors":[]},"links":{"html":"https://pith.science/pith/UZIQVCZURPE6EQZVK4XNANZBJS","json":"https://pith.science/pith/UZIQVCZURPE6EQZVK4XNANZBJS.json","graph_json":"https://pith.science/api/pith-number/UZIQVCZURPE6EQZVK4XNANZBJS/graph.json","events_json":"https://pith.science/api/pith-number/UZIQVCZURPE6EQZVK4XNANZBJS/events.json","paper":"https://pith.science/paper/UZIQVCZU"},"agent_actions":{"view_html":"https://pith.science/pith/UZIQVCZURPE6EQZVK4XNANZBJS","download_json":"https://pith.science/pith/UZIQVCZURPE6EQZVK4XNANZBJS.json","view_paper":"https://pith.science/paper/UZIQVCZU","resolve_alias":"https://pith.science/api/pith-number/resolve?arxiv=2402.08334&json=true","fetch_graph":"https://pith.science/api/pith-number/UZIQVCZURPE6EQZVK4XNANZBJS/graph.json","fetch_events":"https://pith.science/api/pith-number/UZIQVCZURPE6EQZVK4XNANZBJS/events.json","actions":{"anchor_timestamp":"https://pith.science/pith/UZIQVCZURPE6EQZVK4XNANZBJS/action/timestamp_anchor","attest_storage":"https://pith.science/pith/UZIQVCZURPE6EQZVK4XNANZBJS/action/storage_attestation","attest_author":"https://pith.science/pith/UZIQVCZURPE6EQZVK4XNANZBJS/action/author_attestation","sign_citation":"https://pith.science/pith/UZIQVCZURPE6EQZVK4XNANZBJS/action/citation_signature","submit_replication":"https://pith.science/pith/UZIQVCZURPE6EQZVK4XNANZBJS/action/replication_record"}},"created_at":"2026-07-05T07:44:31.112408+00:00","updated_at":"2026-07-05T07:44:31.112408+00:00"}